Marshall Wace LLP Purchases Shares of 53,586 Inhibrx, Inc. (NASDAQ:INBX)

Marshall Wace LLP purchased a new position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 53,586 shares of the company's stock, valued at approximately $825,000. Marshall Wace LLP owned about 0.37% of Inhibrx as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in INBX. HighTower Advisors LLC purchased a new stake in shares of Inhibrx during the 4th quarter worth about $12,039,000. Walleye Capital LLC purchased a new position in shares of Inhibrx during the 4th quarter worth approximately $8,932,000. Slotnik Capital LLC acquired a new stake in shares of Inhibrx in the fourth quarter valued at $5,975,000. Geode Capital Management LLC acquired a new position in Inhibrx in the 4th quarter valued at about $3,930,000. Finally, Kennedy Capital Management LLC acquired a new stake in shares of Inhibrx during the fourth quarter worth about $2,551,000. 82.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, JMP Securities reiterated a "market perform" rating on shares of Inhibrx in a report on Wednesday, January 22nd.

Inhibrx Price Performance

NASDAQ INBX traded up $0.00 during trading hours on Tuesday, hitting $12.33. 8,617 shares of the company were exchanged, compared to its average volume of 193,096. The company has a 50 day moving average of $12.96 and a two-hundred day moving average of $13.90. Inhibrx, Inc. has a 52-week low of $10.80 and a 52-week high of $34.75.

Inhibrx (NASDAQ:INBX - Get Free Report) last posted its quarterly earnings results on Monday, March 17th. The company reported ($3.09) earnings per share for the quarter, missing analysts' consensus estimates of ($2.88) by ($0.21). The business had revenue of $0.10 million during the quarter. Analysts forecast that Inhibrx, Inc. will post 104.88 EPS for the current fiscal year.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.